Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Otsuka Applies for New Indication of Bipolar Disorder for Abilify
February 7, 2011
- Kyowa Kirin Confirms Efficacy of KW-6500 for PD in PIII
February 7, 2011
- Torii Licenses Allergy Immunotherapy Products from ALK
February 7, 2011
- Chugai Seeks Additional Indication for Pegasys
February 7, 2011
- Erbitux plus FOLFOX Prolongs OS: Merck Serono
February 7, 2011
- Januvia Posts Sales of ¥10 Bil. in 2010: MSD
February 7, 2011
- Larger Doses Approved for Acetaminophen in Adults: Showa Yakuhin Kako
February 7, 2011
- The Customer Is KING
February 7, 2011
- Yakult Honsha Aims at Sales of ¥500 Bil. in FY2020
February 7, 2011
- Eisai Applies for Perampanel in the US, Europe
February 7, 2011
- 6-Month Data from PI/II Trial of Collategene Published
February 7, 2011
- Eisai Opens New Company for Cancer Drug Discovery in US
February 7, 2011
- Halaven Receives Positive Opinion from CHMP
February 7, 2011
- Nasivin M Spray Approved as Class 1 OTC Drug
February 7, 2011
- Korosho Withholds Approval of Norspan
January 31, 2011
- Top-Four Generics-Only Firms Expand Production Capacity
January 31, 2011
- PAFSC Committee Recommends Halaven for Approval
January 31, 2011
- TAIYO Pharm. Recalls Two Generics
January 31, 2011
- Dasen to Be Re-designated for Reevaluation
January 31, 2011
- Korosho to Consider Diabetes Treatment Strategy Using Incretin-Related Drugs
January 31, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…